Anne Brooks | Senior Vice President, US Commercial
Iovance Biotherapeutics

Anne Brooks is an experienced biotech and pharmaceutical executive with a 20+ year proven track record of successfully commercializing pharmaceutical products across diseases, technologies and reimbursement models at all stages of product lifecycle, from early stage development, to product launch, to market exclusivity expiry.  She is currently the Senior Vice President, US Commercial at Iovance Biotherapeutics, a commercial and clinical cell therapy company that is pioneering a transformational approach to innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapy for people with cancer.  Anne leads the US Sales, Marketing, Field Market Access and Strategic Accounts teams and is responsible for the US launch of AMTAGVI (lifileucel), an autologous T cell therapy indicated for the treatment of advanced melanoma. Anne joined Iovance in 2019.  Before her current role at the company, she was the SVP of Global Commercial Strategy and Marketing, responsible for the short- and long-term strategy of Iovance’s lead TIL therapy candidates.  Prior to Iovance, Anne served in numerous commercial leadership roles at Teva Pharmaceuticals, most recently as Senior Director of Marketing for Teva’s Specialty Oncology division where she led the launch of BENDEKA® (bendamustine), which generated over $1B in revenue in less than 2 years. Her earlier experience also included commercial roles of increasing responsibility at Cephalon, Gilead Sciences, and Bristol-Myers Squibb Company.